Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity: 2019-2024

Historic Common Equity for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to $253.0 million.

  • Caribou Biosciences' Common Equity fell 49.56% to $141.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.8 million, marking a year-over-year decrease of 49.56%. This contributed to the annual value of $253.0 million for FY2024, which is 31.34% down from last year.
  • Latest data reveals that Caribou Biosciences reported Common Equity of $253.0 million as of FY2024, which was down 31.34% from $368.4 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Common Equity ranged from a high of $387.8 million in FY2021 and a low of -$23.4 million during FY2020.
  • In the last 3 years, Caribou Biosciences' Common Equity had a median value of $300.9 million in 2022 and averaged $307.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 414.04% in 2020, then skyrocketed by 1,754.76% in 2021.
  • Over the past 5 years, Caribou Biosciences' Common Equity (Yearly) stood at -$23.4 million in 2020, then spiked by 1,754.76% to $387.8 million in 2021, then decreased by 22.42% to $300.9 million in 2022, then rose by 22.44% to $368.4 million in 2023, then plummeted by 31.34% to $253.0 million in 2024.